Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix

Hugo G. Schmökel, Franz E. Weber, Gabriela Seiler, Brigitte Von Rechenberg, Jason C. Schense, Peter Schawalder, Jeffrey Hubbell

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective - To report the results of the treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 (nglBMP-2) delivered from a designed fibrin matrix. Study Design - Experimental trial in rodents and prospective clinical study in dogs and cats with nonunion fractures. Animals - Twenty adult female, albino, Sprague-Dawley rats; 8 client-owned cats and dogs. Methods - After development of a fibrin matrix and evaluation of nglBMP-2 in a rodent femoral defect model, 8 consecutive long bone nonunion fractures (no progression in healing in ≥ 3 months), were treated using 300 μg nglBMP-2 in a liquid fibrin precursor, injected into the defect gap after fracture revision and stabilization, or through a stab incision into the fracture site. The fibrin matrix was designed to clot in the wound after 60 seconds and to release the nglBMP-2 continuously over several days. Results - Using only fibrin gel, 7% of the rat femoral defect was filled with new formed bone compared with 79% defect filling using 2ng nglBMP-2 (P = .006). Five and 10 μg nglBMP in fibrin resulted in union of all femoral defects with complete filling of the gap with new bone. Bony bridging and clinical healing was achieved in 7 patients within 24 weeks of administration of nglBMP-2. Conclusions - Application of nglBMP-2 in a functional matrix can induce bone healing. Controlled release of nglBMP-2 from a fibrin matrix mimics the natural fracture hematoma. Clinical Relevance - nglBMP-2/fibrin can successfully replace a cancellous bone autograft in fracture treatment with an associated reduction in graft donor site morbidity and surgical time.

Original languageEnglish
Pages (from-to)112-118
Number of pages7
JournalVeterinary Surgery
Volume33
Issue number2
DOIs
StatePublished - Mar 1 2004
Externally publishedYes

Fingerprint

bone morphogenetic proteins
fibrin
Fibrin
thighs
Thigh
bone fractures
Therapeutics
bones
Bone and Bones
Rodentia
Cats
rodents
Dogs
cats
recombinant human bone morphogenetic protein-2
hematoma
dogs
Bone Fractures
rats
Autografts

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Schmökel, H. G., Weber, F. E., Seiler, G., Von Rechenberg, B., Schense, J. C., Schawalder, P., & Hubbell, J. (2004). Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix. Veterinary Surgery, 33(2), 112-118. https://doi.org/10.1111/j.1532-950x.2004.04018.x

Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix. / Schmökel, Hugo G.; Weber, Franz E.; Seiler, Gabriela; Von Rechenberg, Brigitte; Schense, Jason C.; Schawalder, Peter; Hubbell, Jeffrey.

In: Veterinary Surgery, Vol. 33, No. 2, 01.03.2004, p. 112-118.

Research output: Contribution to journalArticle

Schmökel, HG, Weber, FE, Seiler, G, Von Rechenberg, B, Schense, JC, Schawalder, P & Hubbell, J 2004, 'Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix', Veterinary Surgery, vol. 33, no. 2, pp. 112-118. https://doi.org/10.1111/j.1532-950x.2004.04018.x
Schmökel, Hugo G. ; Weber, Franz E. ; Seiler, Gabriela ; Von Rechenberg, Brigitte ; Schense, Jason C. ; Schawalder, Peter ; Hubbell, Jeffrey. / Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix. In: Veterinary Surgery. 2004 ; Vol. 33, No. 2. pp. 112-118.
@article{cc7abe78a4cd4f71988df51eb16e1b57,
title = "Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix",
abstract = "Objective - To report the results of the treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 (nglBMP-2) delivered from a designed fibrin matrix. Study Design - Experimental trial in rodents and prospective clinical study in dogs and cats with nonunion fractures. Animals - Twenty adult female, albino, Sprague-Dawley rats; 8 client-owned cats and dogs. Methods - After development of a fibrin matrix and evaluation of nglBMP-2 in a rodent femoral defect model, 8 consecutive long bone nonunion fractures (no progression in healing in ≥ 3 months), were treated using 300 μg nglBMP-2 in a liquid fibrin precursor, injected into the defect gap after fracture revision and stabilization, or through a stab incision into the fracture site. The fibrin matrix was designed to clot in the wound after 60 seconds and to release the nglBMP-2 continuously over several days. Results - Using only fibrin gel, 7{\%} of the rat femoral defect was filled with new formed bone compared with 79{\%} defect filling using 2ng nglBMP-2 (P = .006). Five and 10 μg nglBMP in fibrin resulted in union of all femoral defects with complete filling of the gap with new bone. Bony bridging and clinical healing was achieved in 7 patients within 24 weeks of administration of nglBMP-2. Conclusions - Application of nglBMP-2 in a functional matrix can induce bone healing. Controlled release of nglBMP-2 from a fibrin matrix mimics the natural fracture hematoma. Clinical Relevance - nglBMP-2/fibrin can successfully replace a cancellous bone autograft in fracture treatment with an associated reduction in graft donor site morbidity and surgical time.",
author = "Schm{\"o}kel, {Hugo G.} and Weber, {Franz E.} and Gabriela Seiler and {Von Rechenberg}, Brigitte and Schense, {Jason C.} and Peter Schawalder and Jeffrey Hubbell",
year = "2004",
month = "3",
day = "1",
doi = "10.1111/j.1532-950x.2004.04018.x",
language = "English",
volume = "33",
pages = "112--118",
journal = "Veterinary Surgery",
issn = "0161-3499",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix

AU - Schmökel, Hugo G.

AU - Weber, Franz E.

AU - Seiler, Gabriela

AU - Von Rechenberg, Brigitte

AU - Schense, Jason C.

AU - Schawalder, Peter

AU - Hubbell, Jeffrey

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Objective - To report the results of the treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 (nglBMP-2) delivered from a designed fibrin matrix. Study Design - Experimental trial in rodents and prospective clinical study in dogs and cats with nonunion fractures. Animals - Twenty adult female, albino, Sprague-Dawley rats; 8 client-owned cats and dogs. Methods - After development of a fibrin matrix and evaluation of nglBMP-2 in a rodent femoral defect model, 8 consecutive long bone nonunion fractures (no progression in healing in ≥ 3 months), were treated using 300 μg nglBMP-2 in a liquid fibrin precursor, injected into the defect gap after fracture revision and stabilization, or through a stab incision into the fracture site. The fibrin matrix was designed to clot in the wound after 60 seconds and to release the nglBMP-2 continuously over several days. Results - Using only fibrin gel, 7% of the rat femoral defect was filled with new formed bone compared with 79% defect filling using 2ng nglBMP-2 (P = .006). Five and 10 μg nglBMP in fibrin resulted in union of all femoral defects with complete filling of the gap with new bone. Bony bridging and clinical healing was achieved in 7 patients within 24 weeks of administration of nglBMP-2. Conclusions - Application of nglBMP-2 in a functional matrix can induce bone healing. Controlled release of nglBMP-2 from a fibrin matrix mimics the natural fracture hematoma. Clinical Relevance - nglBMP-2/fibrin can successfully replace a cancellous bone autograft in fracture treatment with an associated reduction in graft donor site morbidity and surgical time.

AB - Objective - To report the results of the treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 (nglBMP-2) delivered from a designed fibrin matrix. Study Design - Experimental trial in rodents and prospective clinical study in dogs and cats with nonunion fractures. Animals - Twenty adult female, albino, Sprague-Dawley rats; 8 client-owned cats and dogs. Methods - After development of a fibrin matrix and evaluation of nglBMP-2 in a rodent femoral defect model, 8 consecutive long bone nonunion fractures (no progression in healing in ≥ 3 months), were treated using 300 μg nglBMP-2 in a liquid fibrin precursor, injected into the defect gap after fracture revision and stabilization, or through a stab incision into the fracture site. The fibrin matrix was designed to clot in the wound after 60 seconds and to release the nglBMP-2 continuously over several days. Results - Using only fibrin gel, 7% of the rat femoral defect was filled with new formed bone compared with 79% defect filling using 2ng nglBMP-2 (P = .006). Five and 10 μg nglBMP in fibrin resulted in union of all femoral defects with complete filling of the gap with new bone. Bony bridging and clinical healing was achieved in 7 patients within 24 weeks of administration of nglBMP-2. Conclusions - Application of nglBMP-2 in a functional matrix can induce bone healing. Controlled release of nglBMP-2 from a fibrin matrix mimics the natural fracture hematoma. Clinical Relevance - nglBMP-2/fibrin can successfully replace a cancellous bone autograft in fracture treatment with an associated reduction in graft donor site morbidity and surgical time.

UR - http://www.scopus.com/inward/record.url?scp=2442663178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442663178&partnerID=8YFLogxK

U2 - 10.1111/j.1532-950x.2004.04018.x

DO - 10.1111/j.1532-950x.2004.04018.x

M3 - Article

C2 - 15027972

AN - SCOPUS:2442663178

VL - 33

SP - 112

EP - 118

JO - Veterinary Surgery

JF - Veterinary Surgery

SN - 0161-3499

IS - 2

ER -